Nearly 200 New Medicines in Development for Diabetes
New medicines in development include treatments for type 1 and type 2 diabetes.
America’s biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development, all either in clinical trials or under review by FDA, include 30 for type 1 diabetes, 100 for type 2, and 52 for diabetes-related conditions, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).
According to the report, some of the initiatives being taken against diabetes include treatments that will improve glucose-dependent insulin secretion for type 2 diabetes, inhibit an enzyme linked to diabetic neuropathy, and stimulate and enhance the regeneration of insulin-producing cells for type 1 diabetes.
A new public-private partnership involving the National Institutes of Health, 10 biopharmaceutical companies, PhRMA, and several non-profit disease foundations aims to transform the current model for developing new diagnostics and treatments for certain diseases. The Accelerating Medicines Partnership will begin with three- to five-year pilot projects focused on three disease areas, including diabetes.
Source: Pharmaceutical Research and Manufacturers of America
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
